Trump Administration Drafts 100% Tariff Order on Imported Patented Drugs

The Trump administration has prepared a draft executive order that would impose a 100% tariff on imports of patented medications and their active ingredients. This aggressive trade measure, targeting a critical sector of the pharmaceutical supply chain, could be announced as soon as Thursday, signaling a major escalation in the administration's "America First" trade policy directly into the realm of public health and drug pricing.

The draft order, obtained by STAT, specifically singles out patented drugs and their key components for the punitive tariff. The move, first reported in part by Bloomberg, represents a significant and novel use of trade tools to exert pressure on the pharmaceutical industry. The White House has not commented, and sources caution that the timeline or final details of the plan could still change before any official announcement.

If implemented, the 100% tariff would dramatically increase costs for drugmakers relying on foreign manufacturing, a common practice in the global pharmaceutical industry. This action would inject severe new uncertainty into drug supply chains and could force a rapid reassessment of production and pricing strategies by major pharmaceutical companies. The order places the industry under immediate scrutiny and raises the risk of retaliatory trade measures from affected countries, while also intersecting with the ongoing political debate over high drug prices in the United States.